JPH0698018B2 - 細菌生産物の外在化法 - Google Patents
細菌生産物の外在化法Info
- Publication number
- JPH0698018B2 JPH0698018B2 JP59167705A JP16770584A JPH0698018B2 JP H0698018 B2 JPH0698018 B2 JP H0698018B2 JP 59167705 A JP59167705 A JP 59167705A JP 16770584 A JP16770584 A JP 16770584A JP H0698018 B2 JPH0698018 B2 JP H0698018B2
- Authority
- JP
- Japan
- Prior art keywords
- gene
- lambda
- phage
- genes
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000001580 bacterial effect Effects 0.000 title abstract description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 104
- 241000894006 Bacteria Species 0.000 claims description 37
- 241000588724 Escherichia coli Species 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 33
- 230000035772 mutation Effects 0.000 claims description 30
- 239000004098 Tetracycline Substances 0.000 claims description 18
- 229960002180 tetracycline Drugs 0.000 claims description 18
- 229930101283 tetracycline Natural products 0.000 claims description 18
- 235000019364 tetracycline Nutrition 0.000 claims description 18
- 150000003522 tetracyclines Chemical class 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 239000003550 marker Substances 0.000 claims description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- 241000701959 Escherichia virus Lambda Species 0.000 claims description 11
- 230000002068 genetic effect Effects 0.000 claims description 11
- 101150034144 ci gene Proteins 0.000 claims description 10
- 230000010076 replication Effects 0.000 claims description 8
- 101150084044 P gene Proteins 0.000 claims description 4
- 101150045515 O gene Proteins 0.000 claims description 2
- 238000011144 upstream manufacturing Methods 0.000 claims 2
- 108020004414 DNA Proteins 0.000 abstract description 40
- 230000006870 function Effects 0.000 abstract description 21
- 102000053602 DNA Human genes 0.000 abstract description 4
- 238000012258 culturing Methods 0.000 abstract description 2
- 230000001131 transforming effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 57
- 239000000047 product Substances 0.000 description 29
- 230000002101 lytic effect Effects 0.000 description 24
- 239000012634 fragment Substances 0.000 description 22
- 239000013612 plasmid Substances 0.000 description 18
- 230000037430 deletion Effects 0.000 description 16
- 238000012217 deletion Methods 0.000 description 16
- 230000009089 cytolysis Effects 0.000 description 15
- 241000193830 Bacillus <bacterium> Species 0.000 description 13
- 230000002950 deficient Effects 0.000 description 13
- 230000006698 induction Effects 0.000 description 13
- 230000003834 intracellular effect Effects 0.000 description 10
- 101150036274 kil gene Proteins 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 230000009466 transformation Effects 0.000 description 10
- 241000607142 Salmonella Species 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 239000012141 concentrate Substances 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- XTEGARKTQYYJKE-UHFFFAOYSA-M Chlorate Chemical compound [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 description 8
- 206010042566 Superinfection Diseases 0.000 description 8
- 210000000349 chromosome Anatomy 0.000 description 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 7
- 101710126949 Lysin Proteins 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000026683 transduction Effects 0.000 description 7
- 238000010361 transduction Methods 0.000 description 7
- 108700026215 vpr Genes Proteins 0.000 description 7
- 101100342273 Escherichia coli (strain K12) kilR gene Proteins 0.000 description 6
- 102000016943 Muramidase Human genes 0.000 description 6
- 108010014251 Muramidase Proteins 0.000 description 6
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 6
- 102000005936 beta-Galactosidase Human genes 0.000 description 6
- 108010005774 beta-Galactosidase Proteins 0.000 description 6
- 229960000274 lysozyme Drugs 0.000 description 6
- 235000010335 lysozyme Nutrition 0.000 description 6
- 239000004325 lysozyme Substances 0.000 description 6
- 230000006798 recombination Effects 0.000 description 6
- 238000005215 recombination Methods 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 229960000723 ampicillin Drugs 0.000 description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- -1 red Proteins 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 101150076489 B gene Proteins 0.000 description 3
- 241001646716 Escherichia coli K-12 Species 0.000 description 3
- 102000008016 Eukaryotic Initiation Factor-3 Human genes 0.000 description 3
- 108010089790 Eukaryotic Initiation Factor-3 Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 101150064691 Q gene Proteins 0.000 description 3
- 102000009661 Repressor Proteins Human genes 0.000 description 3
- 108010034634 Repressor Proteins Proteins 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 108700026220 vif Genes Proteins 0.000 description 3
- 238000005725 Campbell reaction Methods 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010055016 Rec A Recombinases Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000004459 forage Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 101000870242 Bacillus phage Nf Tail knob protein gp9 Proteins 0.000 description 1
- 108700003860 Bacterial Genes Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101150111062 C gene Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
- 101150097493 D gene Proteins 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- 101100522841 Drosophila melanogaster pygo gene Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101100145155 Escherichia phage lambda cIII gene Proteins 0.000 description 1
- 102100039554 Galectin-8 Human genes 0.000 description 1
- 101001011019 Gallus gallus Gallinacin-10 Proteins 0.000 description 1
- 101000887168 Gallus gallus Gallinacin-8 Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 101150008942 J gene Proteins 0.000 description 1
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 101150090155 R gene Proteins 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 101150010882 S gene Proteins 0.000 description 1
- 241000701835 Salmonella virus P22 Species 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 241000589196 Sinorhizobium meliloti Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000724233 Staphylococcus virus 11 Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 101150054175 cro gene Proteins 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 101150022010 gam gene Proteins 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 101150062334 int gene Proteins 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000001320 lysogenic effect Effects 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 244000000042 obligate parasite Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/06—Lysis of microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
- C12N15/73—Expression systems using phage (lambda) regulatory sequences
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Bakery Products And Manufacturing Methods Therefor (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/521,517 US4637980A (en) | 1983-08-09 | 1983-08-09 | Externalization of products of bacteria |
US521517 | 1983-08-09 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5184810A Division JPH0714348B2 (ja) | 1983-08-09 | 1993-07-27 | 細菌生産物の外在化に用いるdnaフラグメントおよび細菌 |
JP6071868A Division JPH0787787B2 (ja) | 1983-08-09 | 1994-04-11 | 温度感受性細菌の産生法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS6062985A JPS6062985A (ja) | 1985-04-11 |
JPH0698018B2 true JPH0698018B2 (ja) | 1994-12-07 |
Family
ID=24077058
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP59167705A Expired - Lifetime JPH0698018B2 (ja) | 1983-08-09 | 1984-08-09 | 細菌生産物の外在化法 |
JP5184810A Expired - Lifetime JPH0714348B2 (ja) | 1983-08-09 | 1993-07-27 | 細菌生産物の外在化に用いるdnaフラグメントおよび細菌 |
JP6071868A Expired - Fee Related JPH0787787B2 (ja) | 1983-08-09 | 1994-04-11 | 温度感受性細菌の産生法 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5184810A Expired - Lifetime JPH0714348B2 (ja) | 1983-08-09 | 1993-07-27 | 細菌生産物の外在化に用いるdnaフラグメントおよび細菌 |
JP6071868A Expired - Fee Related JPH0787787B2 (ja) | 1983-08-09 | 1994-04-11 | 温度感受性細菌の産生法 |
Country Status (20)
Country | Link |
---|---|
US (1) | US4637980A (sv) |
EP (1) | EP0140864B1 (sv) |
JP (3) | JPH0698018B2 (sv) |
KR (1) | KR940004545B1 (sv) |
AT (1) | ATE51024T1 (sv) |
AU (1) | AU583014B2 (sv) |
CA (1) | CA1219825A (sv) |
DE (1) | DE3481629D1 (sv) |
DK (1) | DK172672B1 (sv) |
ES (2) | ES8602124A1 (sv) |
FI (1) | FI89507C (sv) |
GR (1) | GR80053B (sv) |
HU (1) | HU197940B (sv) |
IE (1) | IE57797B1 (sv) |
IL (1) | IL72623A (sv) |
NO (1) | NO169242C (sv) |
NZ (1) | NZ209128A (sv) |
PT (1) | PT79045A (sv) |
ZA (1) | ZA846132B (sv) |
ZW (1) | ZW12684A1 (sv) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4894334A (en) * | 1984-03-28 | 1990-01-16 | Cetus Corporation | Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria |
CA1340372C (en) * | 1984-07-09 | 1999-02-02 | John D. Clements | Production of e. coli lt-b enterotoxin subunit |
US5162217A (en) * | 1984-08-27 | 1992-11-10 | Bio-Technology General Corp. | Plasmids for expression of human superoxide dismutase (SOD) analogs containing lambda PL promoter with engineered restriction site for substituting ribosomal binding sites and methods of use thereof |
US5759816A (en) * | 1984-08-27 | 1998-06-02 | Bio-Technology General Corp. | Expression vectors containing λPL promoter and T1 T2 rRNA termination sequence plasmids containing the vectors hosts containing the plasmids and related methods |
TW205070B (sv) * | 1986-06-30 | 1993-05-01 | Takeda Pharm Industry Co Ltd | |
US5646015A (en) * | 1988-08-31 | 1997-07-08 | Astra Ab | Excretion of heterologous proteins from E. coli |
US5223407A (en) * | 1988-08-31 | 1993-06-29 | Allelix Inc. | Excretion of heterologous proteins from e. coli |
US5096815A (en) * | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
US5198346A (en) * | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
US6177083B1 (en) * | 1990-07-26 | 2001-01-23 | Evax Technologies Gmbh | Process for the production of vaccines and their use |
DE4023721A1 (de) * | 1990-07-26 | 1992-01-30 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von vakzinen und ihre verwendung |
GB9223709D0 (en) * | 1992-11-12 | 1992-12-23 | Ici Plc | Process for the separation of protein from microorganisms |
US5468629A (en) * | 1993-04-13 | 1995-11-21 | Calhoun; Cornelia | Method of promoting in vitro homologous recombination transfection in mammalian cells using the RecA protein |
SE9702401D0 (sv) | 1997-06-19 | 1997-06-19 | Astra Ab | Pharmaceutical use |
AU1223600A (en) * | 1998-10-28 | 2000-05-15 | Genentech Inc. | Process |
EP1124941B1 (en) * | 1998-10-28 | 2003-09-17 | Genentech, Inc. | Process for recovering heterologous polypeptides from bacterial cells |
US6268178B1 (en) | 1999-05-25 | 2001-07-31 | Phage Biotechnology Corp. | Phage-dependent super-production of biologically active protein and peptides |
US6479280B1 (en) | 1999-09-24 | 2002-11-12 | Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw | Recombinant phages capable of entering host cells via specific interaction with an artificial receptor |
EP1309716A4 (en) * | 2000-08-15 | 2005-08-03 | Phage Biotechnology Corp | METHOD FOR PRODUCING BIOLOGICALLY ACTIVE HUMAN AZIDES FIBROBLAST GROWTH FACTOR AND USE THEREOF FOR PROMOTING ANGIONESIS |
CA2419203A1 (en) * | 2000-08-15 | 2002-02-21 | Phage Biotechnology Corporation | Phage-dependent superproduction of biologically active protein and peptides |
US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
PL2336153T3 (pl) | 2003-11-21 | 2016-08-31 | Pfenex Inc | Udoskonalone systemy ekspresji z układem wydzielania SEC |
US20050214321A1 (en) * | 2003-12-01 | 2005-09-29 | Dow Global Technologies Inc. | Recombinant icosahedral virus like particle production in pseudomonads |
EP2412816B1 (en) | 2004-07-26 | 2014-12-03 | Pfenex Inc. | Process for improved protein expression by strain engineering |
US7892811B2 (en) * | 2004-08-17 | 2011-02-22 | Zymo Research Corporation | Controlled lysis of bacteria |
CA2677179C (en) | 2007-01-31 | 2016-02-16 | Dow Global Technologies Inc. | Bacterial leader sequences for increased expression |
EP2142651B1 (en) | 2007-04-27 | 2013-05-22 | Pfenex Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
CN101784655A (zh) * | 2007-04-27 | 2010-07-21 | 菲尼克斯股份有限公司 | 可溶性重组二十面体病毒样颗粒的改良生成和体内装配 |
WO2009025690A2 (en) | 2007-05-23 | 2009-02-26 | Nature Technology Corporation | Improved e. coli plasmid dna production |
US8318481B2 (en) * | 2007-12-07 | 2012-11-27 | Pfenex Inc. | High copy number self-replicating plasmids in pseudomonas |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4336336A (en) | 1979-01-12 | 1982-06-22 | President And Fellows Of Harvard College | Fused gene and method of making and using same |
US4338397A (en) | 1980-04-11 | 1982-07-06 | President And Fellows Of Harvard College | Mature protein synthesis |
US4506013A (en) * | 1980-10-03 | 1985-03-19 | Eli Lilly And Company | Stabilizing and selecting recombinant DNA host cells |
EP0061250A3 (en) * | 1981-03-23 | 1983-09-28 | Biogen N.V. | Improved process for recovering products produced by host organisms |
CA1185197A (en) * | 1981-04-30 | 1985-04-09 | Akira Furuya | Lysozyme-sensitive microorganism |
EP0074808A3 (en) * | 1981-09-16 | 1984-07-04 | University Patents, Inc. | Recombinant method and materials |
-
1983
- 1983-08-09 US US06/521,517 patent/US4637980A/en not_active Expired - Lifetime
-
1984
- 1984-08-06 AU AU31638/84A patent/AU583014B2/en not_active Ceased
- 1984-08-07 DE DE8484870113T patent/DE3481629D1/de not_active Expired - Fee Related
- 1984-08-07 NZ NZ209128A patent/NZ209128A/xx unknown
- 1984-08-07 EP EP84870113A patent/EP0140864B1/en not_active Expired - Lifetime
- 1984-08-07 IE IE2021/84A patent/IE57797B1/en not_active IP Right Cessation
- 1984-08-07 AT AT84870113T patent/ATE51024T1/de not_active IP Right Cessation
- 1984-08-07 DK DK198403806A patent/DK172672B1/da not_active IP Right Cessation
- 1984-08-07 GR GR80053A patent/GR80053B/el unknown
- 1984-08-07 FI FI843104A patent/FI89507C/sv not_active IP Right Cessation
- 1984-08-08 CA CA000460500A patent/CA1219825A/en not_active Expired
- 1984-08-08 IL IL72623A patent/IL72623A/xx not_active IP Right Cessation
- 1984-08-08 KR KR1019840004729A patent/KR940004545B1/ko not_active IP Right Cessation
- 1984-08-08 HU HU843033A patent/HU197940B/hu not_active IP Right Cessation
- 1984-08-08 ZA ZA846132A patent/ZA846132B/xx unknown
- 1984-08-08 NO NO843183A patent/NO169242C/no unknown
- 1984-08-08 ES ES534963A patent/ES8602124A1/es not_active Expired
- 1984-08-08 PT PT79045A patent/PT79045A/pt unknown
- 1984-08-08 ZW ZW126/84A patent/ZW12684A1/xx unknown
- 1984-08-09 JP JP59167705A patent/JPH0698018B2/ja not_active Expired - Lifetime
-
1985
- 1985-05-16 ES ES543207A patent/ES8703524A1/es not_active Expired
-
1993
- 1993-07-27 JP JP5184810A patent/JPH0714348B2/ja not_active Expired - Lifetime
-
1994
- 1994-04-11 JP JP6071868A patent/JPH0787787B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH0698018B2 (ja) | 細菌生産物の外在化法 | |
US5840483A (en) | Method of maintaining a desired recombinant gene in a genetic population of cells | |
CA2013573C (en) | Vaccines containing avirulent phop-type microorganisms | |
US7186524B2 (en) | Method for exposing peptides and polypeptides on the cell surface of bacteria | |
EP0437537B1 (en) | Bacterial detection by phage transduction of detectable phenotype | |
Schauer et al. | λ N antitermination system: functional analysis of phage interactions with the host NusA protein | |
US4687737A (en) | Mammalian suppressor genes | |
JP2693948B2 (ja) | 侵入性微生物 | |
EP0095934A2 (en) | Novel bacteriophage and method for breeding thereof | |
JPS59224686A (ja) | 枯草菌変異株における二機能性プラスミドベクタ−の分子クロ−ニング、安定な形質転換枯草菌突然変異株およびその形質転換突然変異株の利用方法 | |
JP2903414B2 (ja) | 抗酸菌分泌発現ベクター及び抗酸菌 | |
US4784952A (en) | Conferred susceptibility to lambda phage in non-coliform procaryotic hosts | |
WO1995010614A1 (en) | Recombinant staphylococcal nucleases and their use in limiting the survival of genetically engineered microorganisms | |
Touati-Schwartz | A new pleiotropic bacteriophage P1 mutation, bof, affecting c 1 repression activity, the expression of plasmid incompatibility and the expression of certain constitutive prophage genes | |
JPH04501501A (ja) | 95kb程度の大きさのdna断片用p1バクテリオフアージクローニング系 | |
JPS58501406A (ja) | エシエリヒア・コリ−における蛋白合成発現の高揚 | |
Jenkins et al. | Male-specific bacteriophage MS2 propagation in fluorophenylalanine-resistant Escherichia coli K12 | |
Kado | Host-vector systems for genetic engineering of higher plant cells | |
KR101970471B1 (ko) | Ctx 파지에 감염되고 콜레라 독소를 생산할 수 있는 비브리오 콜레라 균주 | |
Ben-Gurion et al. | New antibiotic substance produced by Salmonella Typhimurium LT2 | |
Ou et al. | Escherichia coli K-12 F− mutants that form mating aggregates but form transconjugants with low frequencies | |
Lynch | The Role Of Recombination In Gonococcal Pilin Gene Variation | |
EP0635061A1 (en) | A method of limiting the survival of genetically engineered microorganisms in their environment | |
Kano et al. | Polarity in segments of the Escherichia coli trp operon with deleted intraoperonic translational initiation signals | |
JPS60118188A (ja) | 新規な組み換え体dνa |